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ABSTRACT
We previously reported that microRNA (miR)-29b is down-regulated and has
a tumor suppressor role in acute myeloid leukemia (AML). However, little is known
about the mechanisms responsible for miR-29b expression downregulation in AML.
In this work we screened for mutations that could affect miR-29b expression. Using
Sanger sequencing, we identified a germline thymidine (T) base deletion within
the miR-29b-1/miR-29a cluster precursor in 16% of AML patients. Remarkably we
found a significant enrichment for the presence of the miR-29 polymorphism in core
binding factor (CBF) newly diagnosed AML patients (n = 61/303; 20%) with respect
to age, sex and race matched controls (n = 43/402:11%, P < 0.01). Mechanistically,
this polymorphism affects the expression ratio of mature miR-29b and miR-29a by
dampening the processing of miR-29a. RNA immunoprecipitation assays showed
reduced DROSHA binding capacity to the polymorphism with respect to the controls.
Finally, we showed that this polymorphism negatively impacts the ability of miR29b-1/miR-29a cluster to target MCL-1 and CDK6, both known miR-29 targets.

INTRODUCTION

peripheral blood (PB) [1]. Structural genetic alterations,
including gene deletion, inversions and translocations have
been found in about 55 to 60% of AML patients [1, 2].
These alterations, for the most part, represent the initial and
contributing events leading to malignant transformation
[1, 2]. Patients with cytogenetically normal AML (CN-

Acute myeloid leukemia (AML) is a highly
heterogeneous malignant disease of the hematopoietic
system characterized by a clonal accumulation of immature
myeloid precursor cells in the bone marrow (BM) and
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AML) comprise from 30 to 50% of newly diagnosed AML
cases and exhibit striking differences at the molecular level
resulting in a substantial heterogeneity in terms of clinical
outcome [1–5].
Over the past decade, a novel class of small noncoding RNAs, named microRNAs (miRNAs) have
been shown to regulate gene expression by binding to
target mRNAs of protein-coding genes and inhibiting
protein translation and/or causing RNA degradation [6].
Deregulation of miRNAs, and in turn their target genes,
has been found to contribute to malignant transformation in
several human solid tumors and hematologic malignancies
by interfering with the expression of proteins involved in
critical cell processes such as development, differentiation,
proliferation and apoptosis [6, 7]. We and others have shown
unique miRNA expression signatures that are associated
with genetic and molecular subsets of AML [8–12].
Among the miRNAs whose expression is deregulated in
AML, we have focused on miR-29 family members for
several reasons. First, the miR-29 family is composed of
3 isoforms arranged in 2 clusters: miR-29b-1/miR-29a
located on chromosome 7q32 and miR-29b-2/miR-29c
located on chromosome 1q23. Interestingly, chromosome
7q32 is a region frequently deleted in myelodysplastic
syndromes (MDSs) and therapy-related AML [13].
Second, miR-29 family members have been shown to be
down-regulated in several cancers including high-risk
chronic lymphocytic leukemia (CLL) [14], lung cancer
[15], invasive breast cancer [16], cholangiocarcinoma [17]
and rhabdomyosarcoma [18]. Third, we have previously
shown that miR-29b expression is down-regulated in CNAML with wild type nucleophosmin (NPM1) [19], c-KIT
mutated core binding factor (CBF) [20], monosomy 7
or del7q [21] and t(11q23) [8] patients. Last, restoration
of miR-29b expression in AML cell lines and primary
AML blasts induces apoptosis and dramatically reduces
tumorigenicity in a xenograft leukemia model [21]. We have
also shown that miR-29b is central to regulation of both
DNA methylation and tyrosine kinase receptor activities in
leukemia cells [20, 22]. Altogether, these studies support a
tumor suppressor function for miR-29b in AML.
However, with the exception of AML cases where
chromosome 7 is deleted [21], little is known about how
miR-29b expression is down-regulated in AML. Since
miRNAs expression could be lost due to mutations [14], in
this work we screened AML patient samples for mutations
that could affect miR-29b expression and function.

cluster genomic DNA region located in chromosome 7q32
(including 200 base pairs (bp) at the 5′ of the miR-29b-1
and at the 3′ of the miR-29a precursor, Figure 1A) in a
representative cohort of 100 primary AML samples (MD
Anderson cohort, See Table 1 for patient characteristics).
We focus on this cluster because it is located in a fragile
genomic area that is commonly deleted and mutated in
hematological malignancies, including AML [13]. Using
Sanger sequencing we identified a (T) base deletion within
the miR-29b-1/miR-29a cluster precursor miRNAs (at
–385 bp from the 3′ position of the miR-29b precursor and
–264 bp from the 5′ position of miR-29a in chromosome
7q32) in 16/100 (16%) patients (Chr7:130,877,074delT)
(Figure 1B). This deletion correspond to an A base
deletion described in the positive (+) strand at the same
position (rs67760566) in the dbSNP database; http://
www.ncbi.nlm.nih.gov/SNP/. The T base deletion was
observed in 3/10 inv(16) and 7/62 CN-AML patients,
while the other 6 cases were distributed among complex
karyotype (CK) (2/11), isolated –7 (1/5), 11q23 (1/4) and
other cytogenetics (2/5). For the most part, the T base
deletion was heterozygous (n = 14), while in the cases of
isolated monosomy 7 and in –7 associated with CK, the
remaining alleles have the T base deletion. To investigate
whether this genomic finding was somatic or germline,
we sequenced the same genomic region but using buccal
mucosa DNA from two patients who were identified
as positive for the T base deletion. We confirmed that
the same heterozygous T base deletion was observed
in these two cases, supporting a germline origin (data
not shown). Next, to investigate the frequency of this
abnormality in the healthy population, we sequenced
only the genomic area where this T base deletion was
observed (about 200 bp) using genomic DNA obtained
from PB mononuclear cells of 402 healthy individuals of
similar sex and race to the MD Anderson leukemic cohort,
except for White-Hispanics that were more frequent in the
MD Anderson cohort (n = 14/100) vs. the OSU healthy
controls (n = 29/402), P = 0.04 (Supplementary Table 1).
We found that the frequency of this polymorphism in the
control healthy population was 11% (43/402 cases) (38
heterozygous and 5 homozygous) (Supplementary Table 1
and Table 2). There were no differences with respect to the
frequency of this polymorphism according to race or sex
(Supplementary Table 2). The frequency of the miR-29
polymorphism was not significantly different between
AML cases (n = 100: 16%) and controls (n = 402: 11%,
P = 0.16). While not statistically significant, we found an
enrichment for the presence of the miR-29 polymorphism
in AML cases with CBF leukemia (n = 3/12: 25%)
compared to controls (n = 43/402:11%) (Supplementary
Table 1 and Figure 1C). To further explore this finding
we screened for the presence of this polymorphism in a
larger second cohort of 303 samples of newly diagnosed
AML patients with t(8;21) (n = 131) and inv(16)
(n = 172) obtained from the CALGB/ Alliance leukemia

RESULTS
A thymidine (T) base deletion polymorphism
within the miR-29b-1/miR-29a cluster precursor
is enriched in core binding factor AML
To screen for mutations that may affect miR-29b
expression, we sequenced the whole miR-29b-1/miR-29a
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Prognostic impact of the miR-29 polymorphism
in CBF leukemia

tissue bank (See Tables 2 and 3 for patients characteristics).
The polymorphism frequency was significantly higher
in CBF leukemia (61/303, 20%) than healthy controls
(43/402, 11%) of similar sex and race (P < 0.01) (Table 2
and Figure 1C). Only 8 of the 61 CBF-AML patients
with polymorphism were homozygous for the finding.
There were no significant differences in baseline clinical
characteristics among inv(16) and t(8;21) patients with
or without the polymorphism (Table 3), except in t(8;21)
AML cases for age (median polymorphism 45 vs. median
no polymorphism 37, P = 0.04), race (white polymorphism
n = 17 (61%) vs. white no polymorphism n = 91 (90%)
(P < 0.01); platelet count (median polymorphism
47 × 109/L vs. median no polymorphism 36 × 109/L,
P = 0.03) and percentage of blasts in peripheral blood
(median polymorphism 28 vs. median no polymorphism
39, P = 0.04).

To investigate whether this polymorphism has
any prognostic impact in CBF-AML, we assessed the
frequency of complete response (CR), event free-survival
(EFS) and overall survival (OS) according to the miR-29
polymorphism status in a subset of de novo inv(16)
(n = 126) and t(8;21) (n = 100) AML patients treated with
intensive cytarabine/-anthracycline-based first-line therapy
on CALGB/ Alliance trials and whose clinical follow-up
information was available.
First, we investigated whether the presence of the
polymorphism predicts induction chemotherapy response.
We did not observed any differences in the CR rates among
the patients with and without the polymorphism; CR
response rate for t(8;21) cases with miR-29 polymorphism

Figure 1: Frequency of thymidine (T) base deletion (rs67760466) in acute myeloid leukemia (AML). (A) Diagram showing

both miR-29 clusters and the location of the T base deletion. (B) Chromatograms showing a wild type (WT) and a polymorphism case.
(C) Frequency of the polymorphism (rs67760466) in AML patients and in controls. P values were obtained using the Fisher’s exact test.
Patient characteristics are detailed in Tables 1 and 2.
www.impactjournals.com/oncotarget
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Table 1: Patient characteristics for MD Anderson cohort
Characteristic

Value

Age
Median

56

Range

17–82

Sex, no.
Female

47

male

53

Race, no
White

92

Non-white

8

Asian

1

Black

7

Cytogenetics, no.
t(15;17)

1

inv(16)

10

t(8;21)

2

t(11q23)

4

Complex karyotype (CK)

11

isolated 7

5

Other cytogenetics

5

Normal Karyotype

62

FLT3-ITD

18

NPM1

34

n = 19 (90%) vs. cases with no miR-29 polymorphism
n = 76 (96%) (P = 0.28); inv(16) cases with miR-29
polymorphism n = 25(100%) vs. no miR-29 polymorphism
n = 98 (97%) (P = 1.00). Likewise, there were no statistical
significant differences in EFS or OS between CBF patients
with or without miR-29 polymorphism (Supplementary
Figure 1A–1D). These results also held when considering
patients with high risk CBF leukemia based on the presence
of c-KIT mutation (Supplementary Figures 2A–2D
and 3A–3D).

WT samples (23.2 vs. 43.5 respectively, P = 0.02, t-test)
(Figure 2A). These results suggest that the processing of
this miRNA cluster is altered by the polymorphism. To
confirm this possibility, we cloned the miR-29b-1/miR29a cluster from 1 patient harboring the polymorphism
into p-Retro Super plasmid and transfected into K562
cells (which have very low levels of endogenous
miR-29 expression) along with WT (miR-29b-1/miR29a cluster with no polymorphism) and empty vector
constructs. Northern blotting performed 24 and 48
hours after transfection revealed an accumulation of the
miR-29a precursor while the mature miR-29a level was
decreased by 2 fold at 48 and 72 hours (Figure 2B and
Supplementary Figure 4). While the precursor of miR-29b
was also increased at 24 and 48 hours after transfection,
the level of mature miR-29b was unchanged for all time
points (up to 72 hours). Taken together, these data support
that the polymorphism affects the processing of miR-29a.
Given that Drosha complex is required for the processing
of the primary transcript primiR-29b-1/miR-29a, we
evaluated the efficiency of the interaction between the
DROSHA complex and the primiR-29b-1/miR-29a by
performing RIP assays in K562 ells transfected with either

The miR-29b-1/miR-29a cluster processing is
affected by the T base deletion polymorphism
To investigate whether this polymorphism affects
miR-29b or miR-29a mature expression we measured
miR-29b and miR-29a expression in 45 from the 100
primary AML samples (MD Anderson data set), where
RNA was also available. Although mature miR-29a
and miR-29b levels were not significantly different in
polymorphism (n = 10) versus WT (n = 35) samples
(data not shown), we observed that the miR-29a/miR-29b
ratios were significantly lower in the polymorphism than
www.impactjournals.com/oncotarget
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Table 2: Patient characteristics and results for CALGB/ Alliance cohort and controls
*
P values
t(8;21)
inv(16)
All Cases
Controls
t(8;21) vs.
Characteristic
(n = 131)
Age
Median
38
Range
(17–71)
Sex, no. (%)
Male
78 (60)
Female
53 (40)
Race, no. (%)
White
108 (84)
Non-white
21 (16)
Asian
4
Black
13
Other
2
Unknown
2
Polymorphism, no (%)
Yes
28 (21)

P values
inv(16) vs.

P values
All cases vs.

*

*

(n = 172)

(n = 303)

(n = 402)

controls

controls

controls

38
(17–60)

38
(17–71)

42
(18–61)

0.07

<0.01

<0.01

107 (62)
65 (38)

185 (61)
118 (39)

232 (58)
170 (42)

0.76

0.35

0.40

149 (89)
18 (11)
0
16
2
5

257 (87)
39 (13)
4
29
4
7

360 (91)
36 (9)
11
25
0
6

0.03#

0.53#

0.11#

33 (19)

61 (20)

43 (11)

<0.01

<0.01

<0.01

No
103 (79)
139 (81)
242 (80)
359 (89)
P-values for categorical variables were obtained using Fisher exact test, P-values for continuous variables are from
Wilcoxon rank sum test.
#
P-value is for White versus Non-white comparison.
*

miR-29b-1/miR-29a polymorphism, miR-29b-1/miR-29a
WT or empty vector construct. As shown in Figure 2C, the
polymorphism showed reduced Drosha binding capacity
when compared with the WT.

for the cluster harboring the polymorphism (Figure 3C
and 3D). Finally, we investigated whether the less efficient
reduction in Mcl-1 protein expression caused by the
polymorphism was functionally important. Since Mcl-1
is an anti-apoptotic protein [21], we compared apoptosis
induction between the WT and polymorphism miR-29b-1/
miR-29a cluster over-expression in K562 cell lines. In
Figure 3E, we showed that the miR-29b-1/miR-29a cluster
harboring the polymorphism exhibited less apoptosis that
the WT with respect to controls (empty vectors).

The polymorphism dampens the targeting
efficiency and tumor suppressor function of miR29b-1/miR-29a cluster
To assess whether this polymorphism affects miR29 targeting efficiency, we co-transfected a reporter
luciferase construct containing the 3′ untranslated
region (3′UTR) of two known miR-29 target oncogenes,
MCL-1 and CDK6 [21] with the WT, empty vector and
polymorphism harboring miR-29b-1/miR-29a cluster
and performed luciferase assays. Interestingly, relative
normalized luciferase activities were less inhibited with
the polymorphism cluster than the WT construct for
MCL-1 (relative reduction WT: 63%, polymorphism:
80%, P = 0.02, t-test) (Figure 3A) and for CDK6 (relative
reduction WT: 37%, polymorphism: 68%, P < 0.01,
t-test) (Figure 3B). Next, we investigated whether the
effects observed at the luciferase assays were translated
to the protein level. Indeed, we showed that Mcl-1 and
Cdk6 protein down-regulation elicited by the ectopic WT
cluster overexpression was stronger than the one observed
www.impactjournals.com/oncotarget

DISCUSSION
Our results identify a germline polymorphism
within the miR-29b-1/miR-29-a cluster, whose frequency
is increased in the subset of CBF-AML patients with
respect to the normal population. These results were
further validated using a second independent large cohort
of 303 de novo CBF-AML patients (including both
inv(16) and t(8;21)). The causes for such an increased
frequency of this polymorphism in this AML subset are
unknown. Interestingly, miR-29b plays a critical role in
c-KIT oncogene expression regulation in CBF leukemia by
dampening c-KIT oncogene transcription through the direct
targeting of its activator Sp1 [20]. Ectopic overexpression
of miR-29b in CBF-cell lines and in a murine AML model
4358
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Table 3: Clinical and molecular characteristics by polymorphism status in CALGB/ Alliance t(8;21) and inv(16) AML
patients
t(8;21)
inv(16)
No
No
Polymorphism
Polymorphism
Polymorphism Polymorphism
Characteristic
Age
Median
Range
Sex, no. (%)
Male
Female
Race, no. (%)
White
Non-white
Asian
Black
Other
unknown
Hemoglobin (g/dl)
Median
Range

P values

(n = 33)

(n = 139)

37
(17–71)

0.04

36
(17–57)

40
(18–60)

17 (61)
11 (39)

61 (59)
42 (41)

1.00

20 (61)
13 (39)

87 (63)
52 (37)

0.84

17 (61)
11 (39)

91 (90)
10 (10)

<0.01#

26 (81)
6 (19)

123 (91)
12 (9)

0.12#

3
6
0
0

1
7
2
2

0
6
0
1

0
10
2
4

8.7
(5.9–13.3)

8.8
(3.5–12.7)

0.92

9.4
(6.3–12.3)

8.7
(3.1–14.8)

0.07

36
(5–369)

0.03

45
(9–113)

40
(7–272)

0.43

10.8
(0.7–138.9)

0.53

36.0
(0.4–265)

32.53
(1.8–500)

0.98

39
(0–92)

0.04

53
(12–84)

54
(0–97)

0.88

49
(11–97)

0.68

57
(22–86)

58
(2–93)

0.59

24 (24)
17
6
1
76 (76)

0.62#$

9 (27)
2
6
1
24 (73)

34 (24)
11
21
2
105 (76)

0.82$

(n = 28)

(n = 103)

45
(19–69)

Platelet count (x109/L)
Median
47
Range
(7–227)
WBC count (x109)
Median
11.8
Range
(2.2–59.2)
% Blood blasts
Median
28
Range
(6–90)
% Bone Marrow blasts
Median
56
Range
(21–83)
C-KIT, no. (%)
Mutated
exon 17
exon 8
Both
Wild-type

8 (30)
5
2
1
19 (70)

*

P values

*

0.31

unknown
1
3
P-values for categorical variables were obtained using Fisher exact test, P-values for continuous variables are from
Wilcoxon rank sum test.
#
P-value is for White versus Non-white comparison.
$
P-value is for mutated versus wild-type comparison.
*
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represses c-KIT expression and induced cell death [20].
The fact that the miR-29 polymorphism is more prevalent
in CBF leukemia, further support the important functional
role of miR-29 in CBF-leukemia.
Another interesting finding from our work was
the finding of this polymorphism in patients with
isolated chromosome 7 monosomy (1/6). We have
previously shown that patients with monosomy 7 and
del7q primary AML blasts, have lower miR-29a and
miR-29b expression levels than AML blasts without any
chromosome 7 abnormalities, indicating that the structural
genomic deletion is responsible for the decreased miRNA
expression since this cluster is located in chromosome
7q32 [21]. The finding of a polymorphism that affects
the expression and function of this cluster in the other

allele of AML patients with monosomy 7 is intriguing and
may contribute to further inactive the tumor suppressor
functions of the miR-29 cluster.
Mechanistically, this polymorphism affects the
expression ratio of mature miR-29b and miR-29a
by dampening the processing of miR-29a. Northern
blotting showed accumulation of miR-29 precursors
with an associated decrease in the expression of mature
miR-29a. The levels of mature miR-29b however, were
unchanged with respect to the WT controls. Interestingly,
the polymorphism is between miR-29b-1 and miR-29a
and after the miR-29b transcription initiation site, a
possible explanation as to why the polymorphism does
not have an effect on mature miR-29b. In the presence
of reduced mature miR-29a, the accumulation of the

Figure 2: The miR-29b-1/miR-29a cluster processing is affected by the T base deletion polymorphism in acute myeloid
leukemia. (A) miR-29b-1/miR-29a expression ratios in wild type (WT) (n = 35) vs. polymorphism (Poly) cases (n = 10) as measured by

quantitative real time RT-PCR. (B) Northern Blotting (NB) of miR-29b-1/miR-29a after transfection with empty vector (EV), WT or Poly
constructs. U6 was used as loading control. (C) RNA immunoprecipitation assays in K562 cells transfected with miR-29b-1/miR-29a Poly,
WT or EV construct.
www.impactjournals.com/oncotarget
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miR-29a precursor suggests that a problem exists in the
processing of miRNA. Previous groups including our own
have shown that mutations or polymorphisms affecting the
precursor miRNA can affect the miRNA processing and
results in precursor accumulation and decreased mature
miRNA expression [14, 28]. Notably, in the case of the
polymorphism described here the deletion is outside the
miRNA precursor, indicating that the genomic region
between the two miRNAs is important for miRNA
processing of one of the mature miRNAs in the cluster.
The aberrant ratios between miR-29a and miR-29b
resulting from the polymorphism found in the experimental
studies were also confirmed in primary AML samples.
This finding raises the question about the significance
and contribution of the different expression levels among
members of this cluster to the functions of miR-29 in normal
physiological conditions and in disease. We previously

found significant differences in the expression of genes
correlated with miR-29a or miR-29b expression in primary
AML samples, indicating non-overlapping functions for
miR-29a and miR-29b in AML [21]. It is likely that a tight
balance between the expression of both mature miR-29a
and miR-29b exists and alterations in the expression ratios
between them may affect the functions of both miRNAs.
Supporting this, we showed that this polymorphism
negatively impacts the ability of this cluster to target the
oncogenes MCL-1 and CDK6, both known miR-29 targets.
In summary, we discovered a polymorphism in the
miR-29b-1/miR-29a cluster that is enriched in CBF-AML
cases. This polymorphism affects miR-29b-1/miR-29a
cluster processing, resulting in accumulation of the
precursor, and low levels of mature miR-29a. Functionally,
the polymorphism impacts the ability of the cluster to
target MCL-1 and CDK6 and induce apoptosis.

Figure 3: The polymorphism dampens the targeting efficiency and tumor suppressor function of the miR-29b-1/
miR-29a cluster. (A) MCL-1 and (B) CDK6 luciferase Assays. MiR-29b-1/miR-29a wild type (WT), polymorphism (Poly) or empty

vector (EV) constructs were co-transfected with luciferase reporters containing the 3′untranslated regions (UTR) of MCL-1 or CDK6. The
results are shown as relative luciferase values with respect to the EV after normalization with renilla. (C) Western Blotting for Mcl-1 and
(D) Cdk6 proteins in K562 cells after transfection with miR-29b-1/miR-29a WT, Poly or EV constructs. GAPDH was used as loading
control. As a control we also transfected cells with scramble (SC) or miR-29b (29b) oligonucleotides. (E) Apoptosis as measured using
Annexin V/propidium iodine stain in K562 cells after transfection with miR-29b-1/miR-29a WT, Poly or EV constructs.
www.impactjournals.com/oncotarget
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MATERIALS AND METHODS

Cell transfection with miRNA expression vectors
and miRNA precursors

Patients samples

The genomic region corresponding to the miR-29b-1/
miR-29a cluster (200 bp before and after precursor) from a
wild type (WT) or a polymorphism patient was cloned into
the pSuperRetro expression vector (OligoEngine, Seattle,
WA). The miRNA precursor miR-29b was purchased from
Ambion (Austin, TX). Five million K562 cells (ATCC,
Manassas, VA) were nucleoporated using AMAXA
(Gaithersburg, MD) with 5ug of vectors pSuperRetro-miR29a-1/miR-29b-WT, pSurperRetro-miR-29a-1/miR-29bPolymorphism and empty vector or with 5 ug of precursor
oligonucleotides (miR-29b or scrambled controls) in a total
volume of 10 ml.

Frozen diagnostic BM or (PB) samples were obtained
from adult AML patients from the MD Anderson Tissue
bank (n = 100) and from the Cancer and leukemia group
B (CALGB)/ Alliance leukemia tissue bank (n = 303).
Cytogenetic analyses of the samples were performed at
diagnosis, using unstimulated short-term (24-, 48-, and
72-hour) cultures with or without a direct method and
G-banding. For the CALGB/-Alliance dataset, cytogenetic
analyses at diagnosis were performed by CALGB–
approved institutional cytogenetic laboratories as part of
the cytogenetic companion study 8461 and confirmed by
central karyotype review. The criteria used to describe a
cytogenetic clone and description of karyotype followed
the recommendations of the International System for
Human Cytogenetic Nomenclature [23]. FLT3-ITD, FLT3
activation loop D835 and NPM1 mutations analyses were
performed on most of the samples using Sanger sequencing
as previously described [8]. All patients gave informed
consent for cryopreservation and use of the samples
for molecular studies. Approval was obtained from the
institutional board review from the MD Anderson Cancer
Center and The Ohio State University. DNA from the blood
of 402 control healthy subjects was obtained from the Ohio
State University Human Genetics Sample Bank.

Northern blotting
Northern Blotting was performed as previously
described [19]. Briefly, total RNA was extracted using
Trizol reagent (Invitrogen, Carlsbad, CA). RNA samples
(10 ug) were run on 12% polycramide denaturing (urea)
precast gels (BIO-RAD, Hercules, CA) and then transfered
onto Hybond membrane (Amersham Pharmacia Biotech,
Uppsala, Sweden). The hybridization was performed with
α-32P miR-29a and -b labeled probes overnight at 42ºC.
The miR-29 probes sequences were the complementary
one to the mature miR-29s. As a loading control we
measured U6 expression after stripping the filter as
previously described [19].

Mutation screening
To screen for mutations or polymorphisms, the
entire genomic region from primary AML samples,
corresponding to the miR-29b-1/miR-29-a cluster
precursor, located in chromosome 7q32, including 200 bp
at the 5′ and 3′ ends was amplified and sequenced using
the Applied Biosystems DNA sequencing system (Applied
Biosystems, Foster City, CA). When a deviation from the
normal sequence was found, a panel of DNA from the
blood of 402 control subjects was screened to identify
polymorphisms.

RNA immunoprecipitation assay (RIP)
RIP was performed with the Magna RIP kit
(Millipore, Billerica, MA) according to the manufacturer’s
instruction. Cells transfected with vectors pSuperRetromiR-29a-1/miR-29b-WT, pSurperRetro-miR-29a-1/miR29b-Polymorphism and empty vector, were lysed and the
RNA associated proteins were immunoprecipitated (IP)
with Drosha Antibody Cat. Number A301-886A (Bethyl
Laboratories, Montgomery, TX). RNA was extracted from
the Drosha immunoprecipitated complex by following
the protocol provided by the kit and quantified with
Nanodrop2000 (Thermo-Scientific, Waltham, MA). Total
RNA (25 ng) was retro-transcribed with High Capacity
cDNA Reverse Transcription Kit (Lifetech, Carlsbad,
CA). The primiR-29b-1/miR-29a exogenous expression
was assessed by quantitative real time PCR (SYBR green,
Qiagen, Hilden, Germany) and referenced to the nonimmunoprecipitated control (Input) using the following
primers: primiR-29a1/miR-29b Fwd: 5′- CAT ATA TCA
CAA ATG GCA GTC AGG TCT -3′ and Rev: 5′- TGT
ACA GGA TAT CGC ATT GTT GGA A-3′. Real time
PCRs were performed in an Applied Biosystems 7500
instrument. MiRNA expression was measured using Ct
(threshold cycle).

Real-Time quantification of miRs and target
genes
The single tube TaqMan miRNA assays were used
to detect and quantify mature miR-29a and miR-29b
expression as previously described [24] using PCR 9700
Thermocycler ABI Prism 7900HT and the sequence
detection system (Applied Biosystems). To detect the
Myeloid Cell Leukemia sequence 1 (MCL-1) and the
Cyclin-Dependent Kinase 6 (CDK6) mRNA levels, we
used the TaqMan gene expression assays. Normalization
was performed with 18s and U6. Comparative real-time
PCR was performed in triplicate, including no-template
controls. Relative expression was calculated using the
comparative Ct method [25].
www.impactjournals.com/oncotarget
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Statistical analysis

RIPA buffer (SIGMA, St Louis, MO). Protein expression
was analyzed by Western blotting using Mcl-1, Cdk6 and
GAPDH (Santa Cruz, Santa Cruz, CA).

Fisher’s exact test and t-test were used to compare
baseline characteristics and average miRNA expression
between groups of patients [26]. These reported P values
were two-sided and obtained using the SPSS software
package (SPSS 10.0). Baseline demographic, clinical, and
molecular features were compared between the Alliance/
CALGB cohort and controls and between polymorphism
and no polymorphism using the Wilcoxon rank sum and
Fisher’s exact tests for continuous and categorical variables,
respectively [26]. The estimated probabilities of event-free
(EFS) and overall survival (OS) were calculated using the
Kaplan–Meier method, and the log-rank test evaluated
differences between survival distributions [27]. Clinical
endpoint definitions are given in the Data Supplement. All
statistical analyses were performed by the Alliance Statistics
and Data Center on a database locked on June 16, 2016
using SAS 9.4 and TIBCO Spotfire S+ 8.2.
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The 3′ UTR segment containing the target sites
for miR-29b from the MCL-1 gene was amplified by
PCR from genomic DNA and inserted into the pGL3
control vector (Promega, Madison, WI), using the XBA1
site immediately downstream from the stop codon of
luciferase. The following primer sets were used to generate
specific fragments: MCL-1 FW 5′TGGAACTCATT
AGCTGTGTGC3′, and RW 5′GATGCCAATGCAAAA
ACTTG 3′. We also generated an insert with deletions of
4 bp from the site of perfect complementarity using the
Quiagen XL-site directed Mutagenesis Kit. Wild type and
mutant insert were confirmed by sequencing. Human cell
line K562 was grown in 10% fetal bovine serum in RPMI1640. The cells were cotransfected in 10 ml plates using
nucleoporation (Amaxa) according to the manufacturer’s
protocol using 5 ug of the firefly luciferase report vector
and 0.5 ug of the control vector containing Renilla
luciferase, pRL–TK (Promega) along with 5 ug of the
pSuperRetro-miR-29a-1/miR-29b-WT, pSurperRetromiR-29a-1/miR-29b-Polymorphism or empty vector.
Firefly and Renilla luciferase activities were measured
consecutively using the dual luciferase assays (Promega)
24 hrs after transfection.
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